Karel Pacak

List of Publications by Citations

487 papers	27,758 citations	85 h-index	150 g-index
508 ext. papers	32,417 ext. citations	6.7 avg, IF	7.02 L-index

#	Paper	IF	Citations
487	Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 1915-42	5.6	1415
486	Phaeochromocytoma. *Lancet, The*, **2005**, 366, 665-75	40	1229
485	Biochemical diagnosis of pheochromocytoma: which test is best?. *JAMA - Journal of the American Medical Association*, **2002**, 287, 1427-34	27.4	792
484	Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. *Cell Metabolism*, **2014**, 19, 302-9	24.6	513
483	Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 4955-62	5.6	474
482	Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. *Nature Clinical Practice Endocrinology and Metabolism*, **2007**, 3, 92-102		467
481	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. *Lancet Oncology, The*, **2009**, 10, 764-71	21.7	405
480	Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. *Annals of Internal Medicine*, **2001**, 134, 315-29	8	402
479	Preoperative management of the pheochromocytoma patient. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 4069-79	5.6	393
478	Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. *European Journal of Human Genetics*, **2008**, 16, 79-88	5.3	377
477	The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. *Pancreas*, **2010**, 39, 775-83	2.6	371
476	Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 2656-66	5.6	370
475	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. *Cancer Cell*, **2017**, 31, 181-193	24.3	350
474	Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 4757-67	5.6	305
473	Stress-induced norepinephrine release in the hypothalamic paraventricular nucleus and pituitary-adrenocortical and sympathoadrenal activity: in vivo microdialysis studies. *Frontiers in Neuroendocrinology*, **1995**, 16, 89-150	8.9	299
472	Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. *New England Journal of Medicine*, **2012**, 367, 922-30	59.2	288
471	Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. *Journal of Clinical Oncology*, **2007**, 25, 2262-9	2.2	272

470	Malignant pheochromocytoma: current status and initiatives for future progress. *Endocrine-Related Cancer*, **2004**, 11, 423-36	5.7	262
469	High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 4505-9	5.6	255
468	Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 479-91	5.6	251
467	Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. *European Journal of Cancer*, **2012**, 48, 1739-49	7.5	228
466	Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. *Cancer Discovery*, **2013**, 3, 648-57	24.4	228
465	Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 779-86	5.6	228
464	MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. *Clinical Cancer Research*, **2012**, 18, 2828-37	12.9	226
463	Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. *Clinical Chemistry*, **2011**, 57, 411-20	5.5	225
462	Mapping of human brown adipose tissue in lean and obese young men. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 8649-8654	11.5	224
461	Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 1999-2008	5.6	224
460	Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. *Journal of Clinical Oncology*, **2016**, 34, 588-96	2.2	210
459	Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 4083-7	5.6	207
458	Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. *Journal of the National Cancer Institute*, **2012**, 104, 700-8	9.7	197
457	EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2012**, 39, 1977-95	8.8	193
456	Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. *Cancer*, **2008**, 113, 2020-8	6.4	188
455	Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. *JAMA Oncology*, **2016**, 2, 922-8	13.4	187
454	6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. *Hypertension*, **2001**, 38, 6-8	8.5	183
453	Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 2068-75	5.6	178

452	The optimal imaging of adrenal tumours: a comparison of different methods. *Endocrine-Related Cancer*, **2007**, 14, 587-99	5.7	176
451	Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. *Clinical Cancer Research*, **2015**, 21, 3888-95	12.9	175
450	Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. *Journal of Urology*, **2012**, 188, 2063-71	2.5	175
449	Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. *Circulation Research*, **2010**, 106, 193-202	15.7	156
448	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. *Endocrine Reviews*, **2017**, 38, 489-515	27.2	151
447	Clinical review: Current treatment of malignant pheochromocytoma. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1217-25	5.6	147
446	Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. *Clinical Chemistry*, **2005**, 51, 735-44	5.5	145
445	The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 5367-84	5.6	143
444	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). *Modern Pathology*, **2015**, 28, 807-21	9.8	142
443	Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. *Journal of Clinical Oncology*, **2011**, 29, 4137-42	2.2	136
442	A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. *Journal of Molecular Medicine*, **2013**, 91, 507-12	5.5	134
441	Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. *Current Problems in Cancer*, **2014**, 38, 7-41	2.3	132
440	Effects of various stressors on in vivo norepinephrine release in the hypothalamic paraventricular nucleus and on the pituitary-adrenocortical axis. *Annals of the New York Academy of Sciences*, **1995**, 771, 115-30	6.5	132
439	Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 1678-82	5.6	130
438	Functional imaging of endocrine tumors: role of positron emission tomography. *Endocrine Reviews*, **2004**, 25, 568-80	27.2	130
437	Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. *Endocrine-Related Cancer*, **2011**, 18, 97-111	5.7	127
436	Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. *Journal of Nuclear Medicine*, **2008**, 49, 1613-9	8.9	124
435	Mitochondrial Complex II: At the Crossroads. *Trends in Biochemical Sciences*, **2017**, 42, 312-325	10.3	122

434	Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. *Journal of the National Cancer Institute*, **2013**, 105, 1270-83	9.7	122
433	Paternal versus maternal transmission of a stimulatory G-protein alpha subunit knockout produces opposite effects on energy metabolism. *Journal of Clinical Investigation*, **2000**, 105, 615-23	15.9	121
432	68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. *Journal of Nuclear Medicine*, **2016**, 57, 186-91	8.9	120
431	Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. *Reviews in Endocrine and Metabolic Disorders*, **2001**, 2, 297-311	10.5	119
430	Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH?. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E357-66	5.6	116
429	The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. *Journal of Clinical*	5.6	115
428	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2112-2137	8.8	113
427	Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. *Journal of Nuclear Medicine*, **2009**, 50, 1448-54	8.9	113
426	Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. *Antioxidants and Redox Signaling*, **2014**, 20, 267-80	8.4	112
425	New syndrome of paraganglioma and somatostatinoma associated with polycythemia. *Journal of Clinical Oncology*, **2013**, 31, 1690-8	2.2	112
424	Endocrine withdrawal syndromes. *Endocrine Reviews*, **2003**, 24, 523-38	27.2	109
423	Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. *Journal of*	5.6	107
422	PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1784-91	8.8	106
421	Landscape of the mitochondrial Hsp90 metabolome in tumours. *Nature Communications*, **2013**, 4, 2139	17.4	104
420	New imaging approaches to phaeochromocytomas and paragangliomas. *Clinical Endocrinology*, **2010**, 72, 137-45	3.4	104
419	Central nervous system imprinting of the G protein G(s)alpha and its role in metabolic regulation. *Cell Metabolism*, **2009**, 9, 548-55	24.6	104
418	Noradrenergic activation in the paraventricular nucleus during acute and chronic immobilization stress in rats: an in vivo microdialysis study. *Brain Research*, **1992**, 589, 91-6	3.7	104
417	Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells. *Cell Metabolism*, **2019**, 29, 399-416.e10	24.6	104

416	Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E710-9	5.6	102
415	Hypertension in pheochromocytoma: characteristics and treatment. *Endocrinology and Metabolism Clinics of North America*, **2011**, 40, 295-311, vii	5.5	101
414	Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. *Endocrine-Related Cancer*, **2009**, 16, 391-400	5.7	101
413	Is supine rest necessary before blood sampling for plasma metanephrines?. *Clinical Chemistry*, **2007**, 53, 352-4	5.5	96
412	Current approaches and recent developments in the management of head and neck paragangliomas. *Endocrine Reviews*, **2014**, 35, 795-819	27.2	94
411	Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. *Journal of Molecular Medicine*, **2015**, 93, 93-104	5.5	92
410	Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus?. *Annals of the New York Academy of Sciences*, **2006**, 1073, 332-47	6.5	90
409	Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. *Journal of Nuclear Medicine*, **2016**, 57, 1949-1956	8.9	89
408	Effects of immobilization on in vivo release of norepinephrine in the bed nucleus of the stria terminalis in conscious rats. *Brain Research*, **1995**, 688, 242-6	3.7	89
407	The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. *Journal of Nuclear Medicine*, **2007**, 48, 1599-606	8.9	88
406	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 1122-1132	5.6	87
405	Downregulation of metastasis suppressor genes in malignant pheochromocytoma. *International Journal of Cancer*, **2005**, 114, 139-43	7.5	87
404	Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 4826-32	5.6	86
403	Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. *Drug Safety*, **2007**, 30, 1031-62	5.1	85
402	Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **1998**, 275, R1247-55	3.2	85
401	Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism?. *Clinical Science*, **1995**, 88, 533-42	6.5	84
400	Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 3903-11	5.6	83
399	Update on pediatric pheochromocytoma. *Pediatric Nephrology*, **2009**, 24, 943-50	3.2	81

398	Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1248-57	8.8	80
397	False-negative □□□I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. *Endocrine-Related Cancer*, **2012**, 19, 83-93	5.7	80
396	Brown fat imaging with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma. *Journal of Nuclear Medicine*, **2007**, 48, 1077-83	8.9	80
395	Utility of plasma free metanephrines for detecting childhood pheochromocytoma. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 1955-60	5.6	78
394	Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. *Annals of Clinical Biochemistry*, **2013**, 50, 62-9	2.2	77
393	Cardiac sympathetic denervation preceding motor signs in Parkinson disease. *Clinical Autonomic Research*, **2007**, 17, 118-21	4.3	77
392	CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY. *Endocrine Practice*, **2016**, 22, 302-14	3.2	76
391	Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. *Blood*, **2013**, 121, 2563-6	2.2	75
390	Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. *Nuclear Medicine Communications*, **2006**, 27, 31-6	1.6	75
389	New roles of carboxypeptidase E in endocrine and neural function and cancer. *Endocrine Reviews*, **2012**, 33, 216-53	27.2	73
388	Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. *Journal of the National Cancer Institute*, **2001**, 93, 648-9	9.7	73
387	Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). *Clinical Endocrinology*, **2009**, 71, 11-7	3.4	70
386	Metastatic paraganglioma. *Seminars in Oncology*, **2010**, 37, 627-37	5.5	70
385	The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. *European Journal of Endocrinology*, **2007**, 156, 483-7	6.5	70
384	Impaired basal and restraint-induced epinephrine secretion in corticotropin-releasing hormone-deficient mice. *Endocrinology*, **2000**, 141, 1142-50	4.8	70
383	Partial adrenalectomy: underused first line therapy for small adrenal tumors. *Journal of Urology*, **2010**, 184, 18-25	2.5	69
382	Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. *European Journal of Endocrinology*, **2008**, 158, 423-9	6.5	69
381	Drugs and Pheochromocytoma □Don℞ Be Fooled by Every Elevated Metanephrine. *New England Journal of Medicine*, **2011**, 364, 2268-2270	59.2	67

380	15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. *Endocrine-Related Cancer*, **2015**, 22, T135-45	5.7	65
379	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. *Cancers*, **2019**, 11,	6.6	65
378	Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 375-84	5.6	65
377	Pheochromocytoma as an endocrine emergency. *Reviews in Endocrine and Metabolic Disorders*, **2003**, 4, 121-8	10.5	65
376	CRH deficiency impairs but does not block pituitary-adrenal responses to diverse stressors. *Neuroendocrinology*, **2000**, 71, 79-87	5.6	64
375	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. *Journal of Hypertension*, **2020**, 38, 1443-1456	1.9	62
374	Effects of single or repeated immobilization on release of norepinephrine and its metabolites in the central nucleus of the amygdala in conscious rats. *Neuroendocrinology*, **1993**, 57, 626-33	5.6	62
373	Minimal changes in environmental temperature result in a significant increase in energy expenditure and changes in the hormonal homeostasis in healthy adults. *European Journal of Endocrinology*, **2010**, 163, 863-72	6.5	61
372	SDH-related pheochromocytoma and paraganglioma. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2010**, 24, 415-24	6.5	61
371	Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. *Endocrine*, **2017**, 56, 495-503	4	59
370	Subclinical phaeochromocytoma. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2012**, 26, 507-15	6.5	59
369	New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines. *Annals of the New York Academy of Sciences*, **2002**, 970, 29-40	6.5	59
368	Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. *Journal of Urology*, **2010**, 184, 1855-9	2.5	58
367	Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. *Endocrine Pathology*, **2002**, 13, 17-27	4.2	58
366	Plasma metanephrines in renal failure. *Kidney International*, **2005**, 67, 668-77	9.9	57
365	Stress-induced norepinephrine release in the paraventricular nucleus of rats with brainstem hemisections: a microdialysis study. *Neuroendocrinology*, **1993**, 58, 196-201	5.6	57
364	Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. *Journal of the American College of Surgeons*, **2015**, 221, 509-17	4.4	56
363	INCREASED PLASMA NOREPINEPHRINE CONCENTRATION IN CATS WITH INTERSTITIAL CYSTITIS. *Journal of Urology*, **2001**, 165, 2051-2054	2.5	56

362	New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. *Trends in Endocrinology and Metabolism*, **2005**, 16, 66-72	8.8	55
361	Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 637-41	5.6	55
360	Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X. *International Journal of Cancer*, **2014**, 135, 2054-64	7.5	54
359	Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 966-71	11.5	54
358	A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. *Nuclear Medicine and Biology*, **2008**, 35 Suppl 1, S27-34	2.1	54
357	Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. *Endocrine-Related Cancer*, **2008**, 15, 311-23	5.7	54
356	Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. *Frontiers in Endocrinology*, **2018**, 9, 515	5.7	53
355	Interrelations between sympathoadrenal system and hypothalamo-pituitary-adrenocortical/thyroid systems in rats exposed to cold stress. *Journal of Neuroendocrinology*, **1996**, 8, 533-41	3.8	53
354	Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. *Journal of Nuclear Medicine*, **2014**, 55, 1253-9	8.9	52
353	An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. *Journal of Clinical Investigation*, **2011**, 121, 880-92	15.9	52
352	PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics. *Journal of Molecular Diagnostics*, **2017**, 19, 575-588	5.1	51
351	Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings. *Endocrinology*, **2014**, 155, 27-32	4.8	51
350	Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer. *Seminars in Nuclear Medicine*, **2011**, 41, 364-8	5.4	51
349	Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. *European Journal of Endocrinology*, **2005**, 153, 551-63	6.5	51
348	Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. *Clinical and Experimental Metastasis*, **2009**, 26, 239-50	4.7	50
347	Gene expression profiling of benign and malignant pheochromocytoma. *Annals of the New York Academy of Sciences*, **2006**, 1073, 541-56	6.5	50
346	Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications. *Neoplasia*, **2015**, 17, 55-65	6.4	49
345	First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E908-13	5.6	49

344	Pheochromocytoma and paraganglioma. *Progress in Brain Research*, **2010**, 182, 343-73	2.9	49
343	Diagnostic localization of pheochromocytoma: the coming of age of positron emission tomography. *Annals of the New York Academy of Sciences*, **2002**, 970, 170-6	6.5	49
342	Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. *Endocrine-Related Cancer*, **2016**, 23, 899-908	5.7	49
341	New insights into the genetics of familial chromaffin cell tumors. *Annals of the New York Academy of Sciences*, **2002**, 970, 11-28	6.5	48
340	Genomic Landscape of Pheochromocytoma and Paraganglioma. *Trends in Cancer*, **2018**, 4, 6-9	12.5	47
339	Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. *American Journal of Physiology - Endocrinology and Metabolism*, **2008**, 295, E1223-33	6	47
338	Emergencies caused by pheochromocytoma, neuroblastoma, or ganglioneuroma. *Endocrinology and Metabolism Clinics of North America*, **2006**, 35, 699-724, viii	5.5	47
337	Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis. *Endocrine-Related Cancer*, **2019**, 26, 539-550	5.7	47
336	Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 4498-504	5.6	46
335	Genetic testing for pheochromocytoma. *Current Hypertension Reports*, **2010**, 12, 456-64	4.7	46
334	A "pheo" lurks: novel approaches for locating occult pheochromocytoma. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 3641-6	5.6	46
333	Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. *European Journal of Human Genetics*, **2016**, 24, 569-73	5.3	45
332	Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. *Archives of Pathology and Laboratory Medicine*, **2014**, 138, 182-8	5	44
331	SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. *Journal of Cancer Research and Clinical Oncology*, **2017**, 143, 1421-1435	4.9	43
330	Pheochromocytoma and paraganglioma. *Endocrine Practice*, **2015**, 21, 406-12	3.2	43
329	SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. *Surgery*, **2017**, 161, 230-239	3.6	43
328	Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2013**, 20, 186-91	4	43
327	Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions. *Clinical Endocrinology*, **2013**, 79, 170-7	3.4	43

326	Laparoscopic management of extra-adrenal pheochromocytoma. *Journal of Urology*, **2004**, 171, 72-6	2.5	43
325	Familial pheochromocytomas and paragangliomas. *Molecular and Cellular Endocrinology*, **2014**, 386, 92-100	4.4	42
324	Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. *Journal of Molecular Endocrinology*, **2012**, 49, 79-96	4.5	41
323	Radiofrequency ablation of metastatic pheochromocytoma. *Journal of Vascular and Interventional Radiology*, **2009**, 20, 1483-90	2.4	41
322	Current trends in functional imaging of pheochromocytomas and paragangliomas. *Annals of the New York Academy of Sciences*, **2006**, 1073, 374-82	6.5	41
321	Anatomical and functional imaging of metastatic pheochromocytoma. *Annals of the New York Academy of Sciences*, **2004**, 1018, 495-504	6.5	40
320	Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. *Journal of Clinical Oncology*, **2017**, 35, 523-528	2.2	39
319	Prognostic Utility of Total Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors. *Gastroenterology*, **2018**, 154, 998-1008.e1	13.3	39
318	Mutations associated with succinate dehydrogenase D-related malignant paragangliomas. *Clinical Endocrinology*, **2008**, 68, 561-6	3.4	39
317	Effects of hypo- and hyperthyroidism on noradrenergic activity and glycerol concentrations in human subcutaneous abdominal adipose tissue assessed with microdialysis. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 5605-8	5.6	39
316	Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. *Endocrine-Related Cancer*, **2019**, 26, R627-R652	5.7	39
315	Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. *Oncotarget*, **2017**, 8, 56110-56125	3.3	39
314	Targeting NAD/PARP DNA Repair Pathway as a Novel Therapeutic Approach to -Mutated Cluster I Pheochromocytoma and Paraganglioma. *Clinical Cancer Research*, **2018**, 24, 3423-3432	12.9	38
313	Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. *Surgery*, **2017**, 161, 220-227	3.6	38
312	Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. *Endocrinology*, **2013**, 154, 646-55	4.8	38
311	Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma. *Clinical Cancer Research*, **2013**, 19, 3787-95	12.9	38
310	Biochemical diagnosis of pheochromocytoma. *Frontiers of Hormone Research*, **2004**, 31, 76-106	3.5	38
309	Superiority of Ga-DOTATATE over F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 787-797	8.8	38

308	External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma. *Frontiers in Oncology*, **2014**, 4, 166	5.3	37
307	Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. *Oncogene*, **2001**, 20, 7809-11	9.2	37
306	PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS. *Endocrine Practice*, **2017**, 23, 690-704	3.2	36
305	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. *Genetics in Medicine*, **2019**, 21, 705-717	8.1	36
304	The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. *BMC Cancer*, **2014**, 14, 523	4.8	36
303	Chronic hypercortisolemia inhibits dopamine synthesis and turnover in the nucleus accumbens: an in vivo microdialysis study. *Neuroendocrinology*, **2002**, 76, 148-57	5.6	36
302	The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas. *Annals of Surgery*, **2014**, 260, 158-62	7.8	35
301	Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. *Journal of Hypertension*, **2005**, 23, 2033-9	1.9	35
300	Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?. *Journal of the American College of Surgeons*, **2013**, 217, 489-96	4.4	34
299	Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. *Endocrine-Related Cancer*, **2009**, 16, 291-9	5.7	34
298	Diagnosis and localization of pheochromocytoma. *Hypertension*, **2004**, 43, 907-10	8.5	34
297	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. *Genetics in Medicine*, **2018**, 20, 1652-1662	8.1	33
296	The genetic basis of pheochromocytoma and paraganglioma: implications for management. *Urology* , **2014**, 83, 1225-32	1.6	33
295	Clinical utility of chromogranin A in SDHx-related paragangliomas. *European Journal of Clinical Investigation*, **2014**, 44, 365-71	4.6	33
294	Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. *FASEB Journal*, **2012**, 26, 4506-16	0.9	33
293	Metastatic pheochromocytoma: does the size and age matter?. *European Journal of Clinical Investigation*, **2011**, 41, 1121-8	4.6	33
292	G(s)alpha deficiency in adipose tissue leads to a lean phenotype with divergent effects on cold tolerance and diet-induced thermogenesis. *Cell Metabolism*, **2010**, 11, 320-30	24.6	33
291	In vivo micro-CT imaging of liver lesions in small animal models. *Methods*, **2010**, 50, 20-5	4.6	33

290	Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. *Hormones*, **2009**, 8, 111-6	3.1	33
289	Noninvasive monitoring of a murine model of metastatic pheochromocytoma: a comparison of contrast-enhanced microCT and nonenhanced MRI. *Journal of Magnetic Resonance Imaging*, **2009**, 29, 685-91	5.6	32
288	Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. *Journal of Hypertension*, **2007**, 25, 2286-95	1.9	32
287	A new specific succinate-glutamate metabolomic hallmark in SDHx-related paragangliomas. *PLoS ONE*, **2013**, 8, e80539	3.7	32
286	Carboxypeptidase E: elevated expression correlated with tumor growth and metastasis in pheochromocytomas and other cancers. *Cellular and Molecular Neurobiology*, **2010**, 30, 1377-81	4.6	31
285	Glycine stimulates striatal dopamine release in conscious rats. *British Journal of Pharmacology*, **1993**, 110, 50-3	8.6	31
284	Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total Ga-DOTATATE-Avid tumor volume measurements. *European Journal of Endocrinology*, **2017**, 176, 575-582	6.5	30
283	Role of hypoxia and HIF2 in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features. *Advances in Pharmacology*, **2013**, 68, 285-317	5.7	30
282	The adrenal medulla and extra-adrenal paraganglia: then and now. *Endocrine Pathology*, **2014**, 25, 49-58	4.2	30
281	Pheochromocytoma and paraganglioma: current functional and future molecular imaging. *Frontiers in Oncology*, **2011**, 1, 58	5.3	30
280	Elevated inflammation markers in pheochromocytoma compared to other forms of hypertension. *NeuroImmunoModulation*, **2007**, 14, 57-64	2.5	30
279	Brainstem hemisection decreases corticotropin-releasing hormone mRNA in the paraventricular nucleus but not in the central amygdaloid nucleus. *Journal of Neuroendocrinology*, **1996**, 8, 543-51	3.8	30
278	Alternative assembly of respiratory complex II connects energy stress to metabolic checkpoints. *Nature Communications*, **2018**, 9, 2221	17.4	29
277	ZNF367 inhibits cancer progression and is targeted by miR-195. *PLoS ONE*, **2014**, 9, e101423	3.7	29
276	Bilateral adrenal medullary hyperplasia associated with an SDHB mutation. *Journal of Clinical Oncology*, **2011**, 29, e200-2	2.2	29
275	Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma. *Oncogene*, **2002**, 21, 479-82	9.2	29
274	Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy. *PLoS ONE*, **2011**, 6, e14678	3.7	29
273	Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma. *Endocrine-Related Cancer*, **2014**, 21, R261-77	5.7	28

272	Increased uptake of [□□□]meta-iodobenzylguanidine, [□F]fluorodopamine, and [□H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. *Endocrine-Related Cancer*, **2011**, 18, 143-57	5.7	28
271	Survivin: a novel neuroendocrine marker for pheochromocytoma. *European Journal of Endocrinology*, **2002**, 146, 381-8	6.5	28
270	Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **1996**, 354, 287-94	3.4	28
269	Adipocyte □-arrestin-2 is essential for maintaining whole body glucose and energy homeostasis. *Nature Communications*, **2019**, 10, 2936	17.4	27
268	NF-□B inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. *International Journal of Cancer*, **2012**, 131, 2445-55	7.5	27
267	Warburg effect□ manifestation in aggressive pheochromocytomas and paragangliomas: insights from a mouse cell model applied to human tumor tissue. *PLoS ONE*, **2012**, 7, e40949	3.7	27
266	Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. *Hypertension Research*, **2010**, 33, 454-9	4.7	27
265	Brief communication: radiographic contrast infusion and catecholamine release in patients with pheochromocytoma. *Annals of Internal Medicine*, **2009**, 150, 27-32	8	27
264	Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. *Endocrine-Related Cancer*, **2015**, 22, M1-8	5.7	26
263	Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl. *Endocrine-Related Cancer*, **2010**, 17, 581-8	5.7	26
262	MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice. *International Journal of Cancer*, **2006**, 119, 2236-41	7.5	26
261	Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas. *Neoplasia*, **2013**, 15, 435-47	6.4	25
260	The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. *Journal of the Autonomic Nervous System*, **1994**, 50, 93-107		25
259	Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options. *Experimental and Clinical Endocrinology and Diabetes*, **2019**, 127, 117-128	2.3	25
258	Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. *Journal of Nuclear Medicine*, **2017**, 58, 1236-1242	8.9	24
257	Clinical, Diagnostic, and Treatment Characteristics of -Related Metastatic Pheochromocytoma and Paraganglioma. *Frontiers in Oncology*, **2019**, 9, 53	5.3	24
256	18F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas. *European Journal of Clinical Investigation*, **2014**, 44, 325-332	4.6	24
255	Choice of biochemical test for diagnosis of pheochromocytoma: validation of plasma metanephrines. *Current Hypertension Reports*, **2002**, 4, 250-5	4.7	24

254	Role of CRH in glucopenia-induced adrenomedullary activation in rats. *Journal of Neuroendocrinology*, **1993**, 5, 475-86	3.8	24
253	Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease?. *Hormone and Metabolic Research*, **2019**, 51, 458-469	3.1	24
252	Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. *Cell and Tissue Research*, **2018**, 372, 393-401	4.2	23
251	Determinants of central sympathetic activation in spontaneous primary subarachnoid hemorrhage. *Neurocritical Care*, **2012**, 16, 381-8	3.3	23
250	Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors. *JAMA Surgery*, **2019**, 154, 40-45	5.4	23
249	The Evolving Role of Succinate in Tumor Metabolism: An F-FDG-Based Study. *Journal of Nuclear Medicine*, **2017**, 58, 1749-1755	8.9	22
248	Pheochromocytoma: Gasping for Air. *Hormones and Cancer*, **2015**, 6, 191-205	5	22
247	Succinate dehydrogenase gene mutations in cardiac paragangliomas. *American Journal of Cardiology*, **2015**, 115, 1753-9	3	22
246	New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma. *Trends in Endocrinology and Metabolism*, **2017**, 28, 807-817	8.8	22
245	Cerebrospinal fluid catecholamine levels as predictors of outcome in subarachnoid hemorrhage. *Cerebrovascular Diseases*, **2012**, 33, 173-81	3.2	22
244	Leptin concentrations in the abdominal subcutaneous adipose tissue of patients with anorexia nervosa assessed by in vivo microdialysis. *Regulatory Peptides*, **2005**, 128, 63-8		22
243	Differential expression of erythropoietin and its receptor in von hippel-lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 3747-51	5.6	22
242	Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. *Cancers*, **2019**, 11,	6.6	21
241	Carney triad, SDH-deficient tumors, and Sdhb+/- mice share abnormal mitochondria. *Endocrine-Related Cancer*, **2015**, 22, 345-52	5.7	21
240	Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. *Oncotarget*, **2017**, 8, 22313-22324	3.3	21
239	Documenting stress in caregivers of transplantation patients: initial evidence of HPA dysregulation. *Stress*, **2016**, 19, 175-84	3	21
238	Ocular manifestations of hypoxia-inducible factor-2 paraganglioma-somatostatinoma-polycythemia syndrome. *Ophthalmology*, **2014**, 121, 2291-3	7.3	21
237	Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia. *Human Genome Variation*, **2015**, 2, 15053	1.8	21

236	Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. *Clinical Endocrinology*, **2014**, 81, 317-28	3.4	21
235	Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 238-45	5.6	21
234	Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. *BMC Cancer*, **2006**, 6, 131	4.8	21
233	Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fluorodopamine PET. *Journal of Nuclear Medicine*, **2007**, 48, 1940-4	8.9	21
232	Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. *Annals of the New York Academy of Sciences*, **2006**, 1073, 241-52	6.5	21
231	Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and phaeochromocytoma. *Cell and Tissue Research*, **2005**, 322, 443-53	4.2	21
230	Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. *Gland Surgery*, **2020**, 9, 105-123	2.2	21
229	Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. *Surgery*, **2018**, 163, 191-196	3.6	21
228	Quantitative F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 278-282	8.8	20
227	Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. *PLoS ONE*, **2013**, 8, e56083	3.7	20
226	Stressor-specific activation of catecholaminergic systems: implications for stress-related hypothalamic-pituitary-adrenocortical responses. *Advances in Pharmacology*, **1998**, 42, 561-4	5.7	20
225	Chronic blockade of nitric oxide synthesis elevates plasma levels of catecholamines and their metabolites at rest and during stress in rats. *Neurochemical Research*, **1997**, 22, 995-1001	4.6	20
224	Medullary Thyroid Carcinoma: An Update on Imaging. *Journal of Thyroid Research*, **2019**, 2019, 1893047	2.6	19
223	The microenvironment induces collective migration in -silenced mouse pheochromocytoma spheroids. *Endocrine-Related Cancer*, **2017**, 24, 555-564	5.7	19
222	Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?. *Endocrine Pathology*, **2012**, 23, 43-54	4.2	19
221	Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 2952-7	5.6	19
220	Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[18 F]Fluorodopamine Positron Emission Tomography. *Journal of Urology*, **2003**, 169, 274-275	2.5	19
219	Catecholamine physiology and its implications in patients with COVID-19. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 978-986	18.1	19

218	Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 167.e13-20	2.8	18
217	Hypotension in a woman with a metastatic dopamine-secreting carotid body tumor. *Endocrine Practice*, **2003**, 9, 310-4	3.2	18
216	Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. *Current Treatment Options in Oncology*, **2020**, 21, 85	5.4	18
215	Personalized management of pheochromocytoma and paraganglioma. *Endocrine Reviews*, **2021**,	27.2	18
214	Pendrin localizes to the adrenal medulla and modulates catecholamine release. *American Journal of Physiology - Endocrinology and Metabolism*, **2015**, 309, E534-45	6	17
213	18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 1574-1582	5.6	17
212	Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. *Cancer Letters*, **2012**, 316, 46-52	9.9	17
211	The use of functional imaging in a patient with head and neck paragangliomas. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 481-2	5.6	17
210	A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. *American Journal of Pathology*, **2009**, 174, 2051-60	5.8	17
209	Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells. *PLoS ONE*, **2014**, 9, e97712	3.7	17
208	Renaissance of (18)F-FDG positron emission tomography in the imaging of pheochromocytoma/paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 2337-9	5.6	16
207	Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. *Endocrine Pathology*, **2017**, 28, 302-307	4.2	16
206	Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol. *Clinical Nuclear Medicine*, **2014**, 39, 243-50	1.7	16
205	Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling. *Annals of Surgery*, **2009**, 250, 983-90	7.8	16
204	An assessment of biochemical tests for the diagnosis of pheochromocytoma. *Nature Clinical Practice Endocrinology and Metabolism*, **2007**, 3, 744-5		16
203	Targeting NRF2-Governed Glutathione Synthesis for -Mutated Pheochromocytoma and Paraganglioma. *Cancers*, **2020**, 12,	6.6	15
202	Deletion of the von Hippel-Lindau Gene in Hemangioblasts Causes Hemangioblastoma-like Lesions in Murine Retina. *Cancer Research*, **2018**, 78, 1266-1274	10.1	15
201	Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. *Clinical Medicine Insights: Oncology*, **2018**, 12, 1179554918763367	1.8	15

200	Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. *Journal of Neuro-Oncology*, **2016**, 126, 473-81	4.8	15
199	Postoperative Management in Patients with Pheochromocytoma and Paraganglioma. *Cancers*, **2019**, 11,	6.6	15
198	Plasma-free vs deconjugated metanephrines for diagnosis of phaeochromocytoma. *Clinical Endocrinology*, **2013**, 79, 476-83	3.4	15
197	Current and future trends in the anatomical and functional imaging of head and neck paragangliomas. *Seminars in Nuclear Medicine*, **2013**, 43, 462-73	5.4	15
196	Urinary Bladder Paragangliomas: How Immunohistochemistry Can Assist to Identify Patients With SDHB Germline and Somatic Mutations. *American Journal of Surgical Pathology*, **2015**, 39, 1488-92	6.7	15
195	Regulation of Peripheral Catecholamine Responses to Acute Stress in Young Adult and Aged F-344 Rats. *Stress*, **1997**, 2, 113-122	3	15
194	The incidentally discovered adrenal mass. *New England Journal of Medicine*, **2007**, 356, 2005	59.2	15
193	ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice. *Cell Cycle*, **2007**, 6, 1946-50	4.7	15
192	Cardiac uptake-1 inhibition by high circulating norepinephrine levels in patients with pheochromocytoma. *Hypertension*, **2004**, 43, 1227-32	8.5	15
191	HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma. *Endocrine-Related Cancer*, **2016**, 23, L13-6	5.7	15
190	Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2□n Pheochromocytoma Cells. *Cancers*, **2019**, 11,	6.6	14
189	Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 1051-1063	4.9	14
188	The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. *Endocrine-Related Cancer*, **2018**, 25, 893-908	5.7	14
187	Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice. *Endocrinology*, **2014**, 155, 2377-90	4.8	14
186	Malignant paraganglioma associated with succinate dehydrogenase subunit B in an 8-year-old child: the age of first screening?. *Pediatric Nephrology*, **2009**, 24, 1239-42	3.2	14
185	Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells. *Molecular Carcinogenesis*, **2008**, 47, 245-51	5	14
184	Pheochromocytoma: an endocrine stress mimicking disorder. *Annals of the New York Academy of Sciences*, **2008**, 1148, 462-8	6.5	14
183	Drugs and pheochromocytoma--don□ be fooled by every elevated metanephrine. *New England Journal of Medicine*, **2011**, 364, 2268-70	59.2	14

182	Increased plasma norepinephrine concentration in cats with interstitial cystitis. *Journal of Urology*, **2001**, 165, 2051-4	2.5	14
181	The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors. *Hormone and Metabolic Research*, **2019**, 51, 419-436	3.1	14
180	New insights on the pathogenesis of paraganglioma and pheochromocytoma. *F1000Research*, **2018**, 7,	3.6	14
179	F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 812-821	8.8	13
178	HIF-2alpha: AchillesPheel of pseudohypoxic subtype paraganglioma and other related conditions. *European Journal of Cancer*, **2017**, 86, 1-4	7.5	13
177	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. *Cancers*, **2019**, 11,	6.6	13
176	Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy. *Cellular and Molecular Neurobiology*, **2018**, 38, 1099-1106	4.6	13
175	Association between acute sympathetic response, early onset vasospasm, and delayed vasospasm following spontaneous subarachnoid hemorrhage. *Journal of Clinical Neuroscience*, **2014**, 21, 256-62	2.2	13
174	Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma. *European Journal of Endocrinology*, **2015**, 172, 89-95	6.5	13
173	Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas. *Surgery*, **2011**, 150, 1186-93	3.6	13
172	Exercise-induced nausea and vomiting: another sign and symptom of pheochromocytoma and paraganglioma. *Endocrine*, **2010**, 37, 403-7	4	13
171	Hypoxia-Inducible Factor 2Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. *Neoplasia*, **2016**, 18, 567-76	6.4	13
170	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. *Endocrinology*, **2019**, 160, 2600-2617	4.8	12
169	A Transgenic Mouse Model of Pacak?Zhuang Syndrome with An Gain-of-Function Mutation. *Cancers*, **2019**, 11,	6.6	12
168	Therapeutic Targeting of -Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. *Clinical Cancer Research*, **2020**, 26, 3868-3880	12.9	12
167	A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2 positive polycythemia vera: a case report. *BMC Cancer*, **2018**, 18, 286	4.8	12
166	Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma. *Nuclear Medicine and Biology*, **2012**, 39, 215-26	2.1	12
165	Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla. *Cell and Tissue Research*, **2010**, 340, 607-12	4.2	12

164	Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. *Endocrine*, **2008**, 34, 96-100	4	12
163	Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. *Endocrine-Related Cancer*, **2007**, 14, 463-71	5.7	12
162	Characteristics of blood pressure in pheochromocytoma. *Annals of the New York Academy of Sciences*, **2006**, 1073, 86-93	6.5	12
161	A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position. *European Journal of Endocrinology*, **2019**, 181, 301-309	6.5	12
160	HIF2 supports pro-metastatic behavior in pheochromocytomas/paragangliomas. *Endocrine-Related Cancer*, **2020**, 27, 625-640	5.7	12
159	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. *Nature Reviews Endocrinology*, **2021**, 17, 435-444	15.2	12
158	Imaging of Pheochromocytoma and Paraganglioma. *Journal of Nuclear Medicine*, **2021**, 62, 1033-1042	8.9	12
157	Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells. *Cell and Tissue Research*, **2018**, 374, 473-485	4.2	12
156	The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. *Cancers*, **2019**, 11,	6.6	11
155	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. *Journal of Pathology*, **2020**, 251, 378-387	9.4	11
154	Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. *Clinical Endocrinology*, **2016**, 85, 62-9	3.4	11
153	Genetics, diagnosis, and management of medullary thyroid carcinoma and pheochromocytoma/paraganglioma. *Endocrine Practice*, **2014**, 20, 176-87	3.2	11
152	CSF catecholamine profile in subarachnoid hemorrhage patients with neurogenic cardiomyopathy. *Neurocritical Care*, **2011**, 14, 401-6	3.3	11
151	Hyperinsulinemia and sympathoadrenal system activity in the rat. *Annals of the New York Academy of Sciences*, **1997**, 827, 118-34	6.5	11
150	Unexplained symptomatic paroxysmal hypertension in pseudopheochromocytoma: a stress response disorder?. *Annals of the New York Academy of Sciences*, **2008**, 1148, 469-78	6.5	11
149	Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome. *Journal of Endocrinology*, **2007**, 193, 225-33	4.7	11
148	Diagnostic imaging of pheochromocytoma. *Frontiers of Hormone Research*, **2004**, 31, 107-20	3.5	11
147	Characteristic CT features of pheochromocytomas - probability model calculation tool based on a multicentric study. *Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia*, **2019**, 163, 212-219	1.7	11

146	Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2020**, 76, 451-464	15.1	11
145	Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. *Annals of Surgery*, **2019**, 269, 741-747	7.8	11
144	Preoperative Imaging Features are Associated with Surgical Complications Following Carotid Body Tumor Resection. *World Journal of Surgery*, **2015**, 39, 2084-9	3.3	10
143	Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. *PET Clinics*, **2015**, 10, 477-86	2.2	10
142	Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice. *Endocrinology*, **2017**, 158, 3097-3108	4.8	10
141	Pathology of Human Pheochromocytoma and Paraganglioma Xenografts in NSG Mice. *Endocrine Pathology*, **2017**, 28, 2-6	4.2	10
140	Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines. *PLoS ONE*, **2014**, 9, e87807	3.7	10
139	Anatomical and functional imaging of tumors in animal models: focus on pheochromocytoma. *Annals of the New York Academy of Sciences*, **2006**, 1073, 392-404	6.5	10
138	Triiodothyronine attenuates estradiol-induced increases in dopamine D-2 receptor number in rat anterior pituitary. *Brain Research*, **1996**, 712, 148-52	3.7	10
137	Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells. *American Journal of Cancer Research*, **2015**, 5, 1558-70	4.4	10
136	Phosphoprotein-based biomarkers as predictors for cancer therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 18401-18411	11.5	10
135	Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker. *International Journal of Cancer*, **2020**, 146, 2326-2335	7.5	10
134	In vivo detection of catecholamines by magnetic resonance spectroscopy: A potential specific biomarker for the diagnosis of pheochromocytoma. *Surgery*, **2016**, 159, 1231-3	3.6	9
133	Determination of the unmetabolised (18)F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas. *Medical and Biological Engineering and Computing*, **2016**, 54, 103-11	3.1	9
132	Local sympathetic function in human skeletal muscle and adipose tissue assessed by microdialysis. *Clinical Autonomic Research*, **2002**, 12, 13-9	4.3	9
131	A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/- rats. *Endocrine-Related Cancer*, **2020**, 27, 337-354	5.7	9
130	Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models. *Oncotarget*, **2016**, 7, 40531-40545	3.3	9
129	WHY TAKE THE RISK? WE ONLY LIVE ONCE: THE DANGERS ASSOCIATED WITH NEGLECTING A PRE-OPERATIVE ALPHA ADRENOCEPTOR BLOCKADE IN PHEOCHROMOCYTOMA PATIENTS. *Endocrine Practice*, **2019**, 25, 106-108	3.2	9

128	Prospective evaluation of Ga-DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. *Clinical Endocrinology*, **2018**, 89, 155-163	3.4	9
127	Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report. *Journal of Neurosurgery: Spine*, **2017**, 26, 501-506	2.8	8
126	MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas. *Journal of Surgical Research*, **2019**, 243, 1-7	2.5	8
125	Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. *Endocrinology*, **2015**, 156, 4094-104	4.8	8
124	Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	8
123	High-Specific-Activity-I-MIBG versus Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. *Clinical Cancer Research*, **2021**, 27, 2989-2995	12.9	8
122	(18)F-DOPA: the versatile radiopharmaceutical. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1187-9	8.8	8
121	Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome. *Cancer*, **2019**, 125, 1258-1266	6.4	8
120	A Clinical Roadmap to Investigate the Genetic Basis of Pediatric Pheochromocytoma: Which Genes Should Physicians Think About?. *International Journal of Endocrinology*, **2018**, 2018, 8470642	2.7	8
119	Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma. *FASEB Journal*, **2017**, 31, 2226-2240	0.9	7
118	High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma. *PLoS ONE*, **2014**, 9, e90458	3.7	7
117	Phospho-mTOR is not upregulated in metastatic SDHB paragangliomas. *European Journal of Clinical Investigation*, **2013**, 43, 970-7	4.6	7
116	Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas. *Annals of Surgery*, **2016**, 263, 582-7	7.8	7
115	What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?. *Endocrine Pathology*, **2021**, 32, 134-153	4.2	7
114	Chiari Malformation Type 1 in -Associated Syndrome. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	6
113	A Previously Unrecognized Monocytic Component of Pheochromocytoma and Paraganglioma. *Endocrine Pathology*, **2019**, 30, 90-95	4.2	6
112	Ivabradine in Catecholamine-Induced Tachycardia in a Patient with Paraganglioma. *New England Journal of Medicine*, **2019**, 380, 1284-1286	59.2	6
111	Eruption of Metastatic Paraganglioma After Successful Therapy with Lu/Y-DOTATOC and Lu-DOTATATE. *Nuclear Medicine and Molecular Imaging*, **2019**, 53, 223-230	1.9	6

110	Functional Imaging Experience in a Germline Fumarate Hydratase Mutation-Positive Patient With Pheochromocytoma and Paraganglioma. *AACE Clinical Case Reports*, **2016**, 2, e176-e181	0.7	6
109	Mass spectrometric quantification of salivary metanephrines-A study in healthy subjects. *Clinical Biochemistry*, **2016**, 49, 983-8	3.5	6
108	Association between sympathetic response, neurogenic cardiomyopathy, and venous thromboembolization in patients with primary subarachnoid hemorrhage. *Acta Neurochirurgica*, **2013**, 155, 1501-10	3	6
107	Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty. *Journal of Pediatric Endocrinology and Metabolism*, **2014**, 27, 837-44	1.6	6
106	Combined corticotropin-releasing hormone and glucocorticoid deficiency does not enhance counterregulatory responses after recurrent hypoglycemia in mice. *Metabolism: Clinical and Experimental*, **2005**, 54, 1259-65	12.7	6
105	Utility of plasma free metanephrines in diagnosis of factitious pheochromocytoma. *Endocrine Practice*, **2006**, 12, 568-71	3.2	6
104	Animal models of pheochromocytoma including NIH initial experience. *Annals of the New York Academy of Sciences*, **2006**, 1073, 300-5	6.5	6
103	Management of Malignant Pheochromocytoma **2002**, 12, 291-299		6
102	A new concept of unopposed beta-adrenergic overstimulation in a patient with pheochromocytoma. *Annals of Internal Medicine*, **2005**, 142, 1026-8	8	6
101	Pheochromocytoma. *Nature Clinical Practice Cardiovascular Medicine*, **2008**, 5, E1		6
100	Succinate Mediates Tumorigenic Effects Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas. *Frontiers in Endocrinology*, **2021**, 12, 589451	5.7	6
99	Endocrine tumors associated with the vagus nerve. *Endocrine-Related Cancer*, **2016**, 23, R371-9	5.7	6
98	Blood collection in unstressed, conscious, and freely moving mice through implantation of catheters in the jugular vein: a new simplified protocol. *Physiological Reports*, **2018**, 6, e13904	2.6	6
97	Metanephrines for Evaluating Palpitations and Flushing. *JAMA - Journal of the American Medical Association*, **2017**, 318, 385-386	27.4	5
96	Development and validation of a comprehensive mutation and deletion detection assay for SDHB, SDHC, and SDHD. *Clinical Biochemistry*, **2010**, 43, 700-4	3.5	5
95	Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: potential clinical and therapeutic relevance. *Endocrinology*, **2007**, 148, 3900-7	4.8	5
94	How do levels of (endogenous) glucocorticoids, interleukin-10 and interleukin-12 relate to multiple sclerosis relapse before, during and after pregnancy?. *Clinical Endocrinology*, **1999**, 50, 818-9	3.4	5
93	New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.. *Cancers*, **2022**, 14,	6.6	5

92	Comprehensive review of evaluation and management of cardiac paragangliomas. *Heart*, **2020**, 106, 1202-1210	5.1	5
91	Cardiometabolic risk factors and health behaviors in family caregivers. *PLoS ONE*, **2017**, 12, e0176408	3.7	5
90	Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. *Frontiers in Endocrinology*, **2021**, 12, 625312	5.7	5
89	RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. *Cancers*, **2018**, 10,	6.6	5
88	Gallbladder Paraganglioma Associated with Mutation: a Potential Pitfall on F-FDOPA PET Imaging. *Nuclear Medicine and Molecular Imaging*, **2019**, 53, 144-147	1.9	4
87	G deficiency in the dorsomedial hypothalamus leads to obesity, hyperphagia, and reduced thermogenesis associated with impaired leptin signaling. *Molecular Metabolism*, **2019**, 25, 142-153	8.8	4
86	Role of Ga-DOTATATE PET/CT in a Case of -Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide. *Nuclear Medicine and Molecular Imaging*, **2020**, 54, 48-52	1.9	4
85	AN AGGRESSIVE TEMPORAL BONE SDHC PARAGANGLIOMA ASSOCIATED WITH INCREASED HIF-2 SIGNALING. *Endocrine Practice*, **2016**, 22, 190-5	3.2	4
84	Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity. *Seminars in Oncology*, **2019**, 46, 385-392	5.5	4
83	Double stable isotope ultra performance liquid chromatographic-tandem mass spectrometric quantification of tissue content and activity of phenylethanolamine N-methyltransferase, the crucial enzyme responsible for synthesis of epinephrine. *Analytical and Bioanalytical Chemistry*, **2013**, 405, 1713-9	4.4	4
82	The role of dopamine in methylene blue-mediated inhibition of estradiol benzoate-induced anterior pituitary hyperplasia in rats. *Neuroscience Letters*, **2001**, 304, 194-8	3.3	4
81	Prognostic and predictive value of nuclear imaging in endocrine oncology. *Endocrine*, **2020**, 67, 9-19	4	4
80	Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome. *JAMA Ophthalmology*, **2020**, 138, 148-155	3.9	4
79	Phaeochromocytoma - advances through science, collaboration and spreading the word. *Nature Reviews Endocrinology*, **2020**, 16, 621-622	15.2	4
78	Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes. *Journal of Nuclear Medicine*, **2020**, 61, 643-645	8.9	4
77	Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations. *Endocrine*, **2018**, 61, 216-223	4	4
76	Germline SUCLG2 Variants in Patients with Pheochromocytoma and Paraganglioma. *Journal of the National Cancer Institute*, **2021**,	9.7	4
75	Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. *Seminars in Nuclear Medicine*, **2021**, 51, 519-528	5.4	4

74	18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. *Journal of Nuclear Medicine*, **2015**, 56, 1849-54	8.9	3
73	Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. *Metabolism: Clinical and Experimental*, **2020**, 110, 154297	12.7	3
72	Mathematical modeling of disease dynamics in SDHB- and SDHD-related paraganglioma: Further step in understanding hereditary tumor differences and future therapeutic strategies. *PLoS ONE*, **2018**, 13, e0201303	3.7	3
71	Pseudopheochromocytoma. *Endocrinology and Metabolism Clinics of North America*, **2019**, 48, 751-764	5.5	3
70	Relevant Discordance Between 68Ga-DOTATATE and 68Ga-DOTANOC in SDHB-Related Metastatic Paraganglioma: Is Affinity to Somatostatin Receptor 2 the Key?. *Clinical Nuclear Medicine*, **2017**, 42, 211-213	1.7	3
69	Reply: 68Ga-DOTATATE PET/CT Versus MRI: Why the Comparison of 68Ga-DOTATATE PET/CT to an Appropriate MRI Protocol Is Essential. *Journal of Nuclear Medicine*, **2017**, 58, 185	8.9	3
68	Mitochondrial localization of human recombinant adenovirus: from evolution to gene therapy. *NeuroImmunoModulation*, **2007**, 14, 221-3	2.5	3
67	Genomic medicine: exploring the basis of a new approach to endocrine hypertension. *Annals of the New York Academy of Sciences*, **2002**, 970, 177-92	6.5	3
66	Sympathoneural and skeletal muscle contributions to plasma dopa responses in pithed rats. *Journal of the Autonomic Nervous System*, **1991**, 35, 169-74		3
65	Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA). *Advanced Therapeutics*, **2020**, 3, 2000044	4.9	3
64	Developmental vascular malformations in EPAS1 gain-of-function syndrome. *JCI Insight*, **2021**, 6,	9.9	3
63	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. *Cancers*, **2021**, 13,	6.6	3
62	Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects. *Hormone and Metabolic Research*, **2019**, 51, 414-418	3.1	3
61	C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. *Journal of Bone and Mineral Research*, **2021**, 36, 315-321	6.3	3
60	A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses. *Journal of Nuclear Medicine*, **2021**, 62, 26S-33S	8.9	3
59	Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. *Langenbeck's Archives of Surgery*, **2017**, 402, 787-798	3.4	2
58	Paraganglioma of the organ of Zuckerkandl associated with a somatic mutation: A case report. *Oncology Letters*, **2017**, 13, 1083-1086	2.6	2
57	PRECISION MEDICINE IN ADRENAL DISORDERS: THE NEXT GENERATION. *Endocrine Practice*, **2017**, 23, 672-679	3.2	2

56	Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: A F-FDOPA PET/CT study in head and neck paragangliomas. *Clinical Endocrinology*, **2019**, 91, 879-884	3.4	2
55	Pheochromocytoma and Paraganglioma Syndromes **2015**, 449-454		2
54	Neuraxial dysraphism in associated syndrome due to improper mesenchymal transition. *Neurology: Genetics*, **2020**, 6, e414	3.8	2
53	Successful induction therapy with sequential CVD followed by high-dose lanreotide in for metastatic SDHB paraganglioma: Case report. *Journal of Clinical and Translational Endocrinology: Case Reports*, **2018**, 7, 8-13	0.5	2
52	Pheochromocytoma/Paraganglioma: Update on Diagnosis and Management. *Contemporary Endocrinology*, **2018**, 261-310	0.3	2
51	Pheochromocytoma: Unmasking the Chameleon **2013**, 123-148		2
50	Effects of hypercortisolemia or hyperinsulinemia on neurochemical indices of catecholamine release and synthesis in conscious rats. *Journal of the Autonomic Nervous System*, **1995**, 54, 104-12		2
49	Epidural anesthesia and hypotension in pheochromocytoma and paraganglioma. *Endocrine-Related Cancer*, **2020**, 27, 519-527	5.7	2
48	18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. *Endocrinology, Diabetes and Metabolism Case Reports*, **2020**, 2020,	1.4	2
47	Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review. *World Journal of Urology*, **2021**,	4	2
46	Some Considerations in Treating Malignant Head and Neck Paragangliomas. *JAMA Otolaryngology - Head and Neck Surgery*, **2020**, 146, 209-210	3.9	2
45	Surgical Resection of Pheochromocytomas and Paragangliomas is Associated with Lower Cholesterol Levels. *World Journal of Surgery*, **2020**, 44, 552-560	3.3	2
44	Phaeochromocytoma and pregnancy: looking towards better outcomes, less fear, and valuable recommendations. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 2-3	18.1	2
43	Sporadic Primary Pheochromocytoma: A Prospective Intra-Individual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using Ga-DOTATATE, FDG, F-FDOPA, and F-FDA). *American Journal of Roentgenology*, **2021**,	5.4	2
42	Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: A F-FDOPA PET/CT study. *Head and Neck*, **2019**, 41, 1565-1571	4.2	1
41	Rapidly Growing Chest Wall Mass in a Case of Sporadic Metastatic Paraganglioma: Imaging With 4 Different PET Radiopharmaceuticals. *Clinical Nuclear Medicine*, **2016**, 41, 399-400	1.7	1
40	Multitracer PET imaging of bone metastases from paraganglioma: peripheral halo of uptake on 18F-FLT PET mismatching with central uptake of 18F-FDOPA, 18F-fluorodopamine, and 18F-FDG. *European Journal of Nuclear Medicine and Molecular Imaging*, **2013**, 40, 1928-9	8.8	1
39	Multidisciplinary management of locally advanced and widely metastatic paraganglioma in a patient with life-threatening compressive symptoms. *Head and Neck*, **2015**, 37, E205-8	4.2	1

38	When is a phaeo not a phaeo? Depression in an adolescent leading to a phaeochromocytoma-like biochemical profile. *Clinical Endocrinology*, **2011**, 75, 567-8	3.4	1
37	Familial pheochromocytomas and paragangliomas associated with mutations of the succinate dehydrogenase genes. *Expert Review of Endocrinology and Metabolism*, **2007**, 2, 399-406	4.1	1
36	Uncommon Endocrine Tumors in Children and Adolescents **2006**, 775-797		1
35	Pheochromocytoma Resection: The Rule of Surgical Divergence. *AACE Clinical Case Reports*, **2016**, 2, e78-e79	0.7	1
34	Pheochromocytoma Hypertensive Crisis **2014**, 139-147		1
33	Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
32	Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?. *Journal of Nuclear Medicine*, **2021**, 62, 1347-1348	8.9	1
31	Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations. *Cancer Immunology, Immunotherapy*, **2021**, 70, 3303-3312	7.4	1
30	Retraction Note to: Carboxypeptidase E: Elevated Expression Correlated with Tumor Growth and Metastasis in Pheochromocytomas and Other Cancers. *Cellular and Molecular Neurobiology*, **2020**, 40, 859	4.6	1
29	Functional significance of germline EPAS1 variants. *Endocrine-Related Cancer*, **2021**, 28, 97-109	5.7	1
28	Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy. *Cancers*, **2021**, 13,	6.6	1
27	Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. *Journal of Nuclear Medicine*, **2021**, 62, 1192-1199	8.9	1
26	A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy. *Endocrine-Related Cancer*, **2021**, 28, 731-744	5.7	1
25	A NECESSITY, NOT A SECOND THOUGHT: PRE-OPERATIVE ALPHA-ADRENOCEPTOR BLOCKADE IN PHEOCHROMOCYTOMA PATIENTS. *Endocrine Practice*, **2019**, 25, 200-201	3.2	0
24	Clinical manifestations of Pacak-Zhuang syndrome in a male pediatric patient. *Pediatric Blood and Cancer*, **2020**, 67, e28096	3	0
23	A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia. *Aging*, **2020**, 12, 5781-5791	5.6	0
22	Diagnostic Accuracy of Salivary Metanephrines in Pheochromocytomas and Paragangliomas. *Clinical Chemistry*, **2021**, 67, 1090-1097	5.5	0
21	Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma. *Frontiers in Endocrinology*, **2020**, 11, 587065	5.7	0

20	Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma. *Frontiers in Endocrinology*, **2021**, 12, 731096	5.7	0
19	A long noncoding RNA-microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas. *Endocrine*, **2021**, 1	4	0
18	Quantitative biomarkers allow the diagnosis of head and neck paraganglioma on multiparametric MRI. *European Journal of Radiology*, **2021**, 143, 109911	4.7	0
17	The Global Reading Room: Nuclear Medicine Imaging of Suspected Paraganglioma. *American Journal of Roentgenology*, **2021**, 217, 1008-1009	5.4	0
16	Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma.. *European Journal of Cancer*, **2022**, 169, 32-41	7.5	0
15	Supportive management of patients with pheochromocytoma/paraganglioma undergoing noninvasive treatment. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2022**, 29, 294-301	4	0
14	Radionuclide Imaging of Head and Neck Paragangliomas **2017**, 269-294		
13	Radionuclide Imaging of Chromaffin Cell Tumors **2017**, 295-319		
12	More on Ivabradine in Tachycardia with Paraganglioma. Reply. *New England Journal of Medicine*, **2019**, 380, 2590	59.2	
11	Uncommon spreading of primary malignant paraganglioma in a patient with SDHB mutation. *Case Reports in Internal Medicine*, **2016**, 4, 63	0	
10	The Author's Reply: inappropriate adrenoreceptor blockade prior to pheochromocytoma removal - "A timely reappraisal." *Clinical Endocrinology*, **2016**, 85, 990-991	3.4	
9	Recent advances in the imaging of pheochromocytomas and paragangliomas. *International Journal of Endocrine Oncology*, **2017**, 4, 137-144	0.3	
8	Management of Pheochromocytoma and Paraganglioma **2017**, 179-206		
7	Imaging Modalities for Pheochromocytoma and Paraganglioma **2017**, 125-138		
6	Commentary. *Clinical Chemistry*, **2013**, 59, 1565	5.5	
5	Response to Letter to the Editor by Dullaart et al.. *Clinical Endocrinology*, **2010**, 72, 569-570	3.4	
4	Catecholamines in the Brain and Responses to Environmental Challenges **2001**, 45-60		
3	Pheochromocytoma Hypertensive Crisis. *Contemporary Endocrinology*, **2021**, 137-145	0.3	

2	SDHD Gene Mutations: Looking Beyond Head and Neck Tumors. *AACE Clinical Case Reports*, **2018**, 4, 186-190	0.7
1	Somatic Mosaicism of EPAS1 Mutations in Pacak-Zhuang Syndrome.. *Endocrine Practice*, **2022**,	3.2